TABLE 3

Characterization of pathogens isolated in phase II from cUTI and pyelonephritis patientsa

AntibioticNo. of tested pathogens% resistant pathogensMIC50 (mg/liter)MIC90 (mg/liter)% of pathogens with additional ciprofloxacin coresistanceProportion of pathogens with both resistances treated with ciprofloxacin (%)Proportion of pathogens with both resistances treated with finafloxacin (%)
Ampicillin17959.2>32>3233.022.818.0
Cefadroxil17912.3NANA54.57.06.6
Cefepime1793.4<1<1100.03.53.3
Cefotaxime1799.5<1>258.85.35.7
Co-amoxiclav17920.741651.414.09.0
Gentamicin1797.8<1292.910.55.7
Imipenem1790.60.19>0.190.00.00.8
Amdinocillin17910.11>138.93.54.1
Nitrofurantoin17911.7<1612842.97.04.1
Piperacillin-tazobactam1792.81.5480.01.82.5
Trimethoprim17930.7<0.5>1650.915.815.6
Nalidixic acid18531.94>12866.124.119.7
Ciprofloxacin18621.0≤0.0332NANANA
Finafloxacin186NA0.1232NANANA
  • a The resistance profiles of the Gram-positive pathogens isolated from the urine specimens of cUTI and pyelonephritis patients at the screening visit in a phase II study were determined. The frequencies of resistance to 14 antibiotics, MIC50 values, and MIC90 values are shown. In addition, the frequencies of pathogens with resistance to the listed antibiotic and ciprofloxacin are shown together with the frequencies of such strains in the different treatment arms of the clinical trial. NA, not applicable.